Quick Answer
AN2 Therapeutics, Inc. reported Stockholders Equity of $53.06 million for the year ending 2025.
- AN2 Therapeutics, Inc. showed a decrease of -35.2% in Stockholders Equity from 2024 to 2025.
- This data is from AN2 Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$23.11 million | Q2 2021: -$29.84 million | Q3 2021: -$38.35 million | Q1 2022: $115.41 million | Q2 2022: $115.86 million | Q3 2022: $105.57 million | Q1 2023: $82.52 million | Q2 2023: $87.76 million | Q3 2023: $138.97 million | Q1 2024: $110.60 million | Q2 2024: $98.35 million | Q3 2024: $87.67 million | Q1 2025: $73.33 million | Q2 2025: $68.84 million | Q3 2025: $60.38 million.
- Over the full 6 years of available data (2020 to 2025), AN2 Therapeutics, Inc.'s Stockholders Equity has grown by 361.1%.
- Historical annual values: Fiscal year 2025: $53.06 million | Fiscal year 2024: $81.85 million | Fiscal year 2023: $124.70 million | Fiscal year 2022: $95.37 million | Fiscal year 2021: -$47.41 million | Fiscal year 2020: -$20.32 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: